Full Press Release Details
NATICK, Mass. , July 25, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $1.809 billion and adjusted earnings per share of $0.18 for the second quarter ended June 30 , 2013. The company reported GAAP earnings of $0.10 per share.
Second quarter results and recent developments:
"We are pleased with our improved performance during the quarter," said Mike Mahoney , president and chief executive officer, Boston Scientific. "As we continue to expand our portfolio, our team is inspired to deliver meaningful innovation to more patients globally."
| Worldwide sales for the second quarter: | |||||||||||||||
| Three Months Ended | |||||||||||||||
| June 30, | % Change | ||||||||||||||
| in millions | 2013 | 2012 | As Reported Basis | Less: Impact of Foreign Currency | Constant Currency Basis | ||||||||||
| Interventional Cardiology | $ | 520 | $ | 549 | (5)% | $ | (15) | (2)% | (3)% | ||||||
| Peripheral Interventions | 199 | 196 | 2% | (6) | (3)% | 5% | |||||||||
| Cardiovascular | 719 | 745 | (4)% | (21) | (3)% | (1)% | |||||||||
| Cardiac Rhythm Management | 475 | 488 | (3)% | (4) | (1)% | (2)% | |||||||||
| Electrophysiology | 36 | 37 | (3)% | (1) | (1)% | (2)% | |||||||||
| Rhythm Management | 511 | 525 | (3)% | (5) | (1)% | (2)% | |||||||||
| Endoscopy | 325 | 311 | 5% | (11) | (3)% | 8% | |||||||||
| Urology/Women's Health | 124 | 126 | (1)% | (3) | (2)% | 1% | |||||||||
| Neuromodulation | 111 | 91 | 21% | 1 | 0% | 21% | |||||||||
| MedSurg | 560 | 528 | 6% | (13) | (3)% | 9% | |||||||||
| Subtotal Core Businesses | 1,790 | 1,798 | 0% | (39) | (2)% | 2% | |||||||||
| Divested Businesses | 19 | 30 | (36)% | 1 | 2% | (38)% | |||||||||
| Worldwide Net Sales | $ | 1,809 | $ | 1,828 | (1)% | $ | (38) | (2)% | 1% | ||||||
| Growth rates are based on actual, non-rounded amounts and may not recalculate precisely. | |||||||||||||||
| Sales growth rates that exclude the impact of changes in foreign currency exchange rates are not prepared in accordance with U.S. GAAP. An explanation of the company's use of these non-GAAP financial measures is included in the exhibits attached to this news release. |
On a consolidated GAAP basis, net income for the second quarter of 2013 was $130 million , or earnings of $0.10 per share. These results included an intangible asset impairment charge, acquisition- and divestiture-related net credits, restructuring-related charges, and amortization expense, of $117 million (after-tax) or $0.08 per share. Adjusted net income for the second quarter of 2013, excluding these net charges, was $247 million , or $0.18 per share.
On a consolidated GAAP basis, net loss for the second quarter of 2012 was $3.578 billion , or $2.51 per share. These results included goodwill and other intangible asset impairment charges, acquisition-related net credits, divestiture-, restructuring- and litigation-related charges and amortization expense, of $3.817 billion or $2.68 per share. Adjusted net income for the second quarter of 2012, excluding these net charges, was $239 million , or $0.17 per share.
Guidance for Third Quarter and Full Year 2013
The company estimates sales for the third quarter of 2013 in a range of $1.700 to $1.760 billion . The company estimates earnings on a GAAP basis in a range of $0.03 to $0.05 per share. Adjusted earnings, excluding acquisition- and restructuring-related charges, divestiture-related net credits and amortization expense; are estimated in a range of $0.14 to $0.16 per share.
The company estimates sales for the full year 2013 in a range of $7.050 to $7.170 billion . The company estimates losses on a GAAP basis in a range of ($0.07) to ($0.01) per share. Adjusted earnings, excluding goodwill and intangible asset impairment charges, acquisition-, restructuring-, and litigation-related charges, divestiture-related net credits and amortization expense; are estimated in a range of $0.67 to $0.71 per share.
Conference Call Information
Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. (ET) . The company will webcast the call to interested parties through its website: www.bostonscientific.com . Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP earnings and adjusted earnings for the third quarter and full year 2013; our financial performance; our business plans; our growth initiatives and expected impact; our positioning for revenue and earnings per share growth; and our product pipeline and its importance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Use of Non-GAAP Financial Information
A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this news release.
| CONTACT: | Denise Kaigler |
| 508-650-8330 (office) | |
| Corporate Affairs & Communications | |
| Boston Scientific Corporation | |
| [email protected] | |
| Peter Lucht | |
| 508-650-8796 (office) | |
| Global Media Relations | |
| Boston Scientific Corporation | |
| [email protected] | |
| Michael Campbell | |
| 508-650-8023 (office) | |
| Investor Relations | |
| Boston Scientific Corporation | |
| [email protected] |
| BOSTON SCIENTIFIC CORPORATION CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS (Unaudited) | |||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||
| June 30, | June 30, | ||||||||||||
| in millions, except per share data | 2013 | 2012 | 2013 | 2012 | |||||||||
| Net sales | $ | 1,809 | $ | 1,828 | $ | 3,570 | $ | 3,694 | |||||
| Cost of products sold | 530 | 578 | 1,108 | 1,209 | |||||||||
| Gross profit | 1,279 | 1,250 | 2,462 | 2,485 | |||||||||
| Operating expenses: | |||||||||||||
| Selling, general and administrative expenses | 661 | 648 | 1,292 | 1,306 | |||||||||
| Research and development expenses | 223 | 213 | 427 | 428 | |||||||||
| Royalty expense | 47 | 48 | 87 | 96 | |||||||||
| Amortization expense | 101 | 99 | 204 | 195 | |||||||||
| Goodwill impairment charge | — | 3,602 | 423 | 3,602 | |||||||||
| Intangible asset impairment charges | 53 | 129 | 53 | 129 | |||||||||
| Contingent consideration expense (benefit) | (18) | 1 | (41) | 11 | |||||||||
| Restructuring charges | 26 | 28 | 36 | 39 | |||||||||
| Gain on divestiture | (34) | — | (40) | — | |||||||||
| Litigation-related charges | — | 69 | 130 | 69 | |||||||||
| 1,059 | 4,837 | 2,571 | 5,875 | ||||||||||
| Operating income (loss) | 220 | (3,587) | (109) | (3,390) | |||||||||
| Other income (expense): | |||||||||||||
| Interest expense | (65) | (64) | (130) | (132) | |||||||||
| Other, net | (3) | 33 | (3) | 27 | |||||||||
| Income (loss) before income taxes | 152 | (3,618) | (242) | (3,495) | |||||||||
| Income tax expense (benefit) | 22 | (40) | (18) | (30) | |||||||||
| Net income (loss) | $ | 130 | $ | (3,578) | $ | (224) | $ | (3,465) | |||||
| Net income (loss) per common share - basic | $ | 0.10 | $ | (2.51) | $ | (0.17) | $ | (2.42) | |||||
| Net income (loss) per common share - assuming dilution | $ | 0.10 | $ | (2.51) | $ | (0.17) | $ | (2.42) | |||||
| Weighted-average shares outstanding | |||||||||||||
| Basic | 1,343.5 | 1,423.2 | 1,347.7 | 1,434.2 | |||||||||
| Assuming dilution | 1,358.6 | 1,423.2 | 1,347.7 | 1,434.2 |
| BOSTON SCIENTIFIC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||
| As of | |||||||||
| June 30, | December 31, | ||||||||
| in millions, except share data | 2013 | 2012 | |||||||
| (Unaudited) | |||||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 530 | $ | 207 | |||||
| Trade accounts receivable, net | 1,278 | 1,217 | |||||||
| Inventories | 842 | 884 | |||||||
| Deferred income taxes | 496 | 433 | |||||||
| Prepaid expenses and other current assets | 352 | 281 | |||||||
| Total current assets | 3,498 | 3,022 | |||||||
| Property, plant and equipment, net | 1,524 | 1,564 | |||||||
| Goodwill | 5,553 | 5,973 | |||||||
| Other intangible assets, net | 6,026 | 6,289 | |||||||
| Other long-term assets | 395 | 306 | |||||||
| $ | 16,996 | $ | 17,154 | ||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
| Current liabilities: | |||||||||
| Current debt obligations | $ | 605 | $ | 4 | |||||
| Accounts payable | 251 | 232 | |||||||
| Accrued expenses | 1,365 | 1,284 | |||||||
| Other current liabilities | 256 | 252 | |||||||
| Total current liabilities | 2,477 | 1,772 | |||||||
| Long-term debt | 3,647 | 4,252 | |||||||
| Deferred income taxes | 1,711 | 1,713 | |||||||
| Other long-term liabilities | 2,558 | 2,547 | |||||||
| Commitments and contingencies | |||||||||
| Stockholders' equity | |||||||||
| Preferred stock, $.01 par value - authorized 50,000,000 | |||||||||
| shares, none issued and outstanding | |||||||||
| Common stock, $.01 par value - authorized 2,000,000,000 | |||||||||
| shares and issued 1,551,642,655 shares as of June 30, | |||||||||
| 2013 and 1,542,347,188 shares as of December 31, 2012 | 16 | 15 | |||||||
| Treasury stock, at cost 212,293,891 shares as of June 30, 2013 | |||||||||
| and 186,635,532 shares as of December 31, 2012 | (1,292) | (1,092) | |||||||
| Additional paid-in capital | 16,470 | 16,429 | |||||||
| Accumulated deficit | (8,673) | (8,449) | |||||||
| Accumulated other comprehensive income (loss), net of tax | 82 | (33) | |||||||
| Total stockholders' equity | 6,603 | 6,870 | |||||||
| $ | 16,996 | $ | 17,154 |
| BOSTON SCIENTIFIC CORPORATION NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS (Unaudited) | |||||||||||||
| Three Months Ended June 30, 2013 | |||||||||||||
| in millions, except per share data | Pre-Tax | Tax Impact (a) | After-Tax | Impact per diluted share | |||||||||
| GAAP net income (loss) | $ | 152 | $ | (22) | $ | 130 | $ | 0.10 | |||||
| Non-GAAP adjustments: | |||||||||||||
| Intangible asset impairment charge | 53 | (8) | 45 | 0.03 | |||||||||
| Acquisition-related net charges (credits) | (12) | (2) | (14) | (0.01) | |||||||||
| Divestiture-related charges (credits) | (32) | 9 | (23) | (0.02) | |||||||||
| Restructuring and restructuring-related net charges (b) | 31 | (8) | 23 | 0.02 | |||||||||
| Amortization expense | 101 | (15) | 86 | 0.06 | |||||||||
| Adjusted net income | $ | 293 | $ | (46) | $ | 247 | $ | 0.18 | |||||
| Three Months Ended June 30, 2012 | |||||||||||||
| in millions, except per share data | Pre-Tax | Tax Impact (a) | After-Tax | Impact per diluted share | |||||||||
| GAAP net income (loss) | $ | (3,618) | $ | 40 | $ | (3,578) | $ | (2.51) | |||||
| Non-GAAP adjustments: | |||||||||||||
| Goodwill impairment charge | 3,602 | (23) | 3,579 | 2.50 | * | ||||||||
| Intangible asset impairment charge | 129 | (19) | 110 | 0.08 | * | ||||||||
| Acquisition-related net charges (credits) | (34) | 13 | (21) | (0.01) | * | ||||||||
| Divestiture-related charges (credits) | 1 | — | 1 | 0.00 | * | ||||||||
| Restructuring and restructuring-related charges (c ) | 33 | (9) | 24 | 0.02 | * | ||||||||
| Litigation-related net charges | 69 | (29) | 40 | 0.03 | * | ||||||||
| Amortization expense | 99 | (15) | 84 | 0.06 | * | ||||||||
| Adjusted net income | $ | 281 | $ | (42) | $ | 239 | $ | 0.17 | |||||
| * Assumes dilution of 5.8 million shares for the three months ended June 30, 2012 for all or a portion of these non-GAAP adjustments. | |||||||||||||
| (a) - Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." | |||||||||||||
| (b) In the three months ended June 30, 2013, pre-tax restructuring charges were $26 million and pre-tax restructuring-related charges were $5 million recorded in selling, general and administrative expenses. | |||||||||||||
| (c) In the three months ended June 30, 2012, pre-tax restructuring charges were $28 million and pre-tax restructuring-related charges were $5 million, of which $2 million was recorded in cost of products sold and $3 million was recorded in selling, general and administrative expenses. | |||||||||||||
| An explanation of our use of these non-GAAP financial measures is provided at the end of this document. |
| BOSTON SCIENTIFIC CORPORATION NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS (Unaudited) | |||||||||||||
| Six Months Ended June 30, 2013 | |||||||||||||
| in millions, except per share data | Pre-Tax | Tax Impact (a) | After-Tax | Impact per diluted share | |||||||||
| GAAP net income (loss) | $ | (242) | $ | 18 | $ | (224) | $ | (0.17) | |||||
| Non-GAAP adjustments: | |||||||||||||
| Goodwill impairment charge | 423 | (2) | 421 | 0.31 | * | ||||||||
| Intangible asset impairment charges | 53 | (8) | 45 | 0.03 | * | ||||||||
| Acquisition-related net charges (credits) | (35) | (1) | (36) | (0.03) | * | ||||||||
| Divestiture-related charges (credits) | (37) | 11 | (26) | (0.02) | * | ||||||||
| Restructuring and restructuring-related net charges (b) | 46 | (12) | 34 | 0.03 | * | ||||||||
| Litigation-related charges | 130 | (48) | 82 | 0.06 | * | ||||||||
| Amortization expense | 204 | (29) | 175 | 0.14 | * | ||||||||
| Adjusted net income | $ | 542 | $ | (71) | $ | 471 | $ | 0.35 | |||||
| Six Months Ended June 30, 2012 | |||||||||||||
| in millions, except per share data | Pre-Tax | Tax Impact (a) | After-Tax | Impact per diluted share | |||||||||
| GAAP net income (loss) | $ | (3,495) | $ | 30 | $ | (3,465) | $ | (2.42) | |||||
| Non-GAAP adjustments: | |||||||||||||
| Goodwill impairment charge | 3,602 | (23) | 3,579 | 2.49 | ** | ||||||||
| Intangible asset impairment charge | 129 | (19) | 110 | 0.08 | ** | ||||||||
| Acquisition-related net charges (credits) | (21) | 11 | (10) | (0.01) | ** | ||||||||
| Divestiture-related charges (credits) | 2 | 2 | — | ** | |||||||||
| Restructuring and restructuring-related charges (c ) | 50 | (13) | 37 | 0.03 | ** | ||||||||
| Litigation-related net charges | 69 | (29) | 40 | 0.03 | ** | ||||||||
| Amortization expense | 195 | (29) | 166 | 0.12 | ** | ||||||||
| Adjusted net income | $ | 531 | $ | (72) | $ | 459 | $ | 0.32 | |||||
| * Assumes dilution of 14.0 million shares for the six months ended June 30, 2013 for all or a portion of these non-GAAP adjustments. | |||||||||||||
| ** Assumes dilution of 7.3 million shares for the six months ended June 30, 2012 for all or a portion of these non-GAAP adjustments. | |||||||||||||
| (a) - Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." | |||||||||||||
| (b) In the six months ended June 30, 2013, pre-tax restructuring charges were $36 million and pre-tax restructuring-related charges were $10 million recorded in selling, general and administrative expenses. | |||||||||||||
| (c) In the six months ended June 30, 2012, pre-tax restructuring charges were $39 million and pre-tax restructuring-related charges were $11 million, of which $6 million was recorded in cost of products sold and $5 million was recorded in selling, general and administrative expenses. | |||||||||||||
| An explanation of our use of these non-GAAP financial measures is provided at the end of this document. |
| BOSTON SCIENTIFIC CORPORATION SEGMENT INFORMATION (Unaudited) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| SEGMENT NET SALES* | June 30, | June 30, | ||||||||||||||
| in millions | 2013 | 2012** | Change | 2013 | 2012** | Change | ||||||||||
| Interventional Cardiology | $ | 537 | $ | 551 | (3)% | $ | 1,050 | $ | 1,149 | (9)% | ||||||
| Peripheral Interventions | 205 | 196 | 5% | 400 | 384 | 4% | ||||||||||
| Cardiovascular | 742 | 747 | (1)% | 1,450 | 1,533 | (5)% | ||||||||||
| Cardiac Rhythm Management | 485 | 494 | (2)% | 970 | 998 | (3)% | ||||||||||
| Electrophysiology | 37 | 37 | (2)% | 72 | 74 | (4)% | ||||||||||
| Rhythm Management | 522 | 531 | (2)% | 1,042 | 1,072 | (3)% | ||||||||||
| Endoscopy | 334 | 309 | 8% | 647 | 607 | 6% | ||||||||||
| Urology/Women's Health | 126 | 125 | 1% | 245 | 243 | 0% | ||||||||||
| Neuromodulation | 111 | 92 | 21% | 200 | 175 | 14% | ||||||||||
| MedSurg | 571 | 526 | 9% | 1,092 | 1,025 | 6% | ||||||||||
| Subtotal Core Businesses | 1,835 | 1,804 | 2% | 3,584 | 3,630 | (1)% | ||||||||||
| Divested Businesses | 19 | 31 | (38)% | 55 | 60 | (7)% | ||||||||||
| Foreign Currency | (45) | (7) | N/A | (69) | 4 | N/A | ||||||||||
| Worldwide Net Sales | $ | 1,809 | $ | 1,828 | (1)% | $ | 3,570 | $ | 3,694 | (3)% | ||||||
| Growth rates are based on actual, non-rounded amounts and may not recalculate precisely. | ||||||||||||||||
| SEGMENT OPERATING INCOME* | Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | |||||||||||||||
| in millions | 2013 | 2012** | 2013 | 2012** | ||||||||||||
| Segment operating income | ||||||||||||||||
| Cardiovascular | $ | 194 | $ | 195 | $ | 364 | $ | 386 | ||||||||
| Rhythm Management | 61 | 77 | 124 | 160 | ||||||||||||
| MedSurg | 183 | 150 | 333 | 283 | ||||||||||||
| Operating income allocated to reportable segments | 438 | 422 | 821 | 829 | ||||||||||||
| Corporate expenses and currency exchange | (77) | (71) | (146) | (155) | ||||||||||||
| Goodwill and other intangible asset impairment charges; and acquisition-, divestiture-, restructuring-, and litigation-related net charges and credits | (40) | (3,839) | (580) | (3,869) | ||||||||||||
| Amortization expense | (101) | (99) | (204) | (195) | ||||||||||||
| Operating income (loss) | $ | 220 | $ | (3,587) | $ | (109) | $ | (3,390) | ||||||||
| *We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency and sales from divested businesses. Sales generated from reportable segments and divested businesses, as well as operating results of reportable segments and corporate expenses, are based on internally-derived standard currency exchange rates, which may differ from year to year, and do not include intersegment profits. We restated segment information for the prior period based on standard currency exchange rates used for the current period in order to remove the impact of foreign currency exchange fluctuations. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker considers to be non-recurring and/or non-operational, such as amounts related to goodwill and other intangible asset impairment charges; acquisition-, divestiture-, restructuring- and litigation-related charges and credits; and amortization expense. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation above. | ||||||||||||||||
| ** We have restated prior year information to conform to current year presentation. | ||||||||||||||||
| An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document. |
| BOSTON SCIENTIFIC CORPORATION WORLDWIDE CARDIAC RHYTHM MANAGEMENT (CRM) AND CORONARY STENT SYSTEM SALES (Unaudited) | |||||||||||||||||||||
| Three Months Ended June 30 | |||||||||||||||||||||
| in millions | U.S. | International | Worldwide | ||||||||||||||||||
| Q2 2013 | Q2 2012 | Q2 2013 | Q2 2012 | Q2 2013 | Q2 2012 | ||||||||||||||||
| Defibrillator systems | $ | 213 | $ | 220 | $ | 129 | $ | 135 | $ | 342 | $ | 355 | |||||||||
| Pacemaker systems | 69 | 64 | 64 | 69 | 133 | 133 | |||||||||||||||
| Total CRM products | $ | 282 | $ | 284 | $ | 193 | $ | 204 | $ | 475 | $ | 488 | |||||||||
| in millions | U.S. | International | Worldwide | ||||||||||||||||||
| Q2 2013 | Q2 2012 | Q2 2013 | Q2 2012 | Q2 2013 | Q2 2012 | ||||||||||||||||
| Drug-eluting stent systems | $ | 117 | $ | 140 | $ | 170 | $ | 178 | $ | 287 | $ | 318 | |||||||||
| Bare-metal stent systems | 5 | 6 | 12 | 16 | 17 | 22 | |||||||||||||||
| Total Coronary Stent Systems | $ | 122 | $ | 146 | $ | 182 | $ | 194 | $ | 304 | $ | 340 | |||||||||
| Six Months Ended June 30 | |||||||||||||||||||||
| in millions | U.S. | International | Worldwide | ||||||||||||||||||
| YTD 2013 | YTD 2012 | YTD 2013 | YTD 2012 | YTD 2013 | YTD 2012 | ||||||||||||||||
| Defibrillator systems | $ | 434 | $ | 449 | $ | 258 | $ | 274 | $ | 692 | $ | 723 | |||||||||
| Pacemaker systems | 132 | 127 | 130 | 139 | 262 | 266 | |||||||||||||||
| Total CRM products | $ | 566 | $ | 576 | $ | 388 | $ | 413 | $ | 954 | $ | 989 | |||||||||
| in millions | U.S. | International | Worldwide | ||||||||||||||||||
| YTD 2013 | YTD 2012 | YTD 2013 | YTD 2012 | YTD 2013 | YTD 2012 | ||||||||||||||||
| Drug-eluting stent systems | $ | 234 | $ | 315 | $ | 345 | $ | 366 | $ | 579 | $ | 681 | |||||||||
| Bare-metal stent systems | 10 | 13 | 25 | 33 | 35 | 46 | |||||||||||||||
| Total Coronary Stent Systems | $ | 244 | $ | 328 | $ | 370 | $ | 399 | $ | 614 | $ | 727 |
| BOSTON SCIENTIFIC CORPORATION BRIC* NET SALES (Unaudited) | ||
| Q2 2013 Percentage change in BRIC Net Sales as compared to Q2 2012 | ||
| Change | Estimated | |
| As Reported | Constant | Impact of |
| Currency | Currency | Foreign |
| Basis | Basis | Currency |
| 29% | 29% | 0% |
| *BRIC - Countries comprised of Brazil, Russia, India and China |
| BOSTON SCIENTIFIC CORPORATION ESTIMATED NON-GAAP NET INCOME PER COMMON SHARE RECONCILIATIONS (Unaudited) | |||||||||||||
| Q3 and Full Year 2013 EPS Guidance | |||||||||||||
| Q3 2013 Estimate | Full Year 2013 Estimate | ||||||||||||
| (Low) | (High) | (Low) | (High) | ||||||||||
| GAAP results | $ | 0.03 | $ | 0.05 | $ | (0.07) | $ | (0.01) | |||||
| Goodwill impairment charge | — | — | 0.31 | 0.31 | |||||||||
| Intangible asset impairment charges | — | — | 0.03 | 0.03 | |||||||||
| Estimated acquisition-related net charges (credits) | 0.02 | 0.02 | 0.01 | 0.00 | |||||||||
| Estimated divestiture-related net credits | (0.01) | (0.01) | (0.02) | (0.02) | |||||||||
| Estimated restructuring-related charges | 0.04 | 0.04 | 0.09 | 0.08 | |||||||||
| Litigation-related charges | — | — | 0.06 | 0.06 | |||||||||
| Estimated amortization expense | 0.06 | 0.06 | 0.26 | 0.26 | |||||||||
| Adjusted results | $ | 0.14 | $ | 0.16 | $ | 0.67 | $ | 0.71 |
An explanation of our use of these non-GAAP financial measures is provided at the end of this document.
Use of Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income and adjusted net income per share that exclude certain amounts, and revenue growth rates that exclude the impact of changes in foreign currency exchange rates. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States .
The GAAP financial measure most directly comparable to adjusted net income is GAAP net income and the GAAP financial measure most directly comparable to adjusted net income per share is GAAP net income per share. To calculate revenue growth rates that exclude the impact of changes in foreign currency exchange rates, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The GAAP financial measure most directly comparable to this non-GAAP financial measure is growth rate percentages using net sales on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.
The following is an explanation of each of the adjustments that management excluded as part of these non-GAAP financial measures for the three and six months ended June 30, 2013 and 2012, and for the forecasted three month period ending September 30, 2013 and full year ending December 31, 2013 , as well as reasons for excluding each of these individual items:
Adjusted Net Income and Adjusted Net Income per Share:
Goodwill and other intangible asset impairment charges - These amounts represent a) a non-cash write-down of our goodwill balance attributable to our global Cardiac Rhythm Management reporting unit in the first quarter of 2013; b) non-cash write-downs of certain intangible asset balances in the second quarter of 2013; c) a non-cash write-down of our goodwill balance attributable to our Europe , Middle East and Africa (EMEA) reporting unit in the second quarter of 2012; and d) a non-cash write-down of certain intangible asset balances in the second quarter of 2012. We remove the impact of non-cash impairment charges from our operating performance to assist in assessing our cash generated from operations. We believe this is a critical metric for us in measuring our ability to generate cash and invest in our growth. Therefore, this charge is excluded from management's assessment of operating performance and is also excluded for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance, particularly in terms of liquidity.
Acquisition-related charges (credits) - These adjustments consist of (a) contingent consideration fair value adjustments, and (b) due diligence, other fees and exit costs. The contingent consideration adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments. Due diligence, other fees and exit costs include legal, tax, severance and other expenses associated with prior acquisitions that are not representative of on-going operations. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.
Divestiture-related expenses (gains) - These amounts represent separation costs or recognized gains associated with the sale of our Neurovascular business in January 2011. Separation costs and gains on the sale represent those associated with the divestiture and are not representative of on-going operations. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.
Discrete tax items - These items represent adjustments of certain tax positions, which were initially established in prior periods as a result of intangible asset impairment charges; acquisition-, divestiture-, restructuring- or litigation-related charges or credits. These adjustments do not reflect expected on-going operating results. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.
Amortization expense - Amortization expense is a non-cash expense and does not impact our liquidity or compliance with the covenants included in our credit facility agreement. Management removes the impact of amortization from our operating performance to assist in assessing our cash generated from operations. We believe this is a critical metric for measuring our ability to generate cash and invest in our growth. Therefore, amortization expense is excluded from management's assessment of operating performance and is also excluded from the measures management uses to set employee compensation. Accordingly, management has excluded amortization expense for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance, particularly in terms of liquidity.
Revenue Growth Rates Excluding the Impact of Changes in Foreign Currency Exchange Rates
Changes in foreign currency exchange rates - The impact of changes in foreign currency exchange rates is highly variable and difficult to predict. Accordingly, management excludes the impact of changes in foreign currency exchange rates for purposes of reviewing revenue growth rates to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.
Adjusted net income, adjusted net income per share and revenue growth rates that exclude certain amounts and/or the impact of changes in foreign currency exchange rates are not in accordance with U.S. GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.
SOURCE Boston Scientific Corporation